RSAC 2026 wrap-up – Week in security with Tony Anscombe This year, AI agents took the center stage – as a defensive capability, but more pressingly as a risk many organizations haven't caught up with ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...